[Abstract] Understanding how immune cells such as macrophages interact with cancer cells is of increasing interest, as cancer treatments move towards combing both targeted-and immuno-therapies in new treatment regimes. This protocol is using THP-1 cells, a human leukemia monocytic cell line that can be differentiated into macrophages. This allows studying the effects of the macrophage secretome on cancer cells (on e.g., growth, drug response or gene expression) in co-cultures without direct cell contact interactions. This is an important aspect as it removes the presence of any phagocytic aspect to changes in the cancer cell number and behaviour. The in vitro THP-1 monocyte differentiation into polarized macrophages was used to study the effects of both M1 and M2 type populations of macrophages on melanoma cells (Smith et al., 2014; Tsuchiya et al., 1980) . M1 type macrophages are classically thought to be tumour suppressing as opposed to M2 type macrophages, which are thought to possess tissue repairing and tumour growth promoting activities.
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Materials and Reagents
12. RPMI 1640 w/L-Glutamine-Bicarbonate (500 ml) (Sigma-Aldrich, catalog number:
R8758)
13. 12-O-tetradecanoylphorbol-l3-acetate (PMA) (Sigma-Aldrich, catalog number: P1585)
14. Recombinant human interferon type gamma (IFN-γ) (Peprotech, catalog number: 
Day 1
THP-1 cells are grown in suspension in RPMI/FCS media, and activation is performed once plated into transwell inserts. Inserts are handled at the sterile edges of the inserts using gloves.
1. THP-1 cells are counted using a haemocytometer a cell suspension with a concentration of 1 x 10 5 cells/ml is made up.
2. One 6 well-plate is then prepared by adding 2 ml of RPMI/FCS media per 6 well. The transwell inserts are then placed into the 6 well containing the 2 ml medium.
3. 2 ml of the THP-1 cell suspension is added into the inserts (2 x 10 5 cells/insert). 
Day 2
Activated THP-1 cells are differentiated in transwell inserts after 24 h in PMA.
1. A new 6 well plate is prepared by adding 2 ml of fresh RPMI/FCS media.
Copyright © 2015 The Authors; exclusive licensee Bio-protocol LLC.
2. The PMA containing media is then aspirated gently from the inserts containing the activated THP-1 cells and the inserts are transferred to the new 6 well plate as described in Figure 1 Day 2.
3. 2 ml of RPMI/FCS media is then added into the inserts and left for 1 h before treatment.
The inserts are then treated with the desired mix of cytokines:
a. M1 differentiation can be achieved either by treating with 15 ng/ml of lipopolysaccharide (LPS) (1.5 µl of stock solution into 4ml) or 50 ng/ml IFN-γ (2 µl of stock solution into 4 ml).
b. M2 differentiation can be achieved by the combined treatment with 25 ng/ml IL4 and 25 ng/ml IL13 (1 µl of stock solution into 4 ml).
c. Undifferentiated but activated THP-1 cells are left untreated in the insert to be used as a reference well for activated but non-differentiated monocytes.
d. Correct differentiation into M1 and M2 type macrophages can be assessed at this stage by immunofluorescence, ELISA or gene expression analysis for specific markers (such as IL1, IL10, ARGINASE) as described in Smith et al. (2014) .
Day 3
The human melanoma cell line to be investigated is pre-plated into 6 well plates. 2. After PBS/EDTA aspiration 1 ml of trypsin/EDTA is added to the flask and then incubated in a 37 °C incubator for 3-5 min.
3. Cells are then re-suspended in 10 ml of DMEM or RPMI (depending on cell line) media and then counted.
4. Depending on the doubling rate of cell line used and the length of the experiment being performed the number of cells plated will vary but usually lie within the region of 0.5-2 x 10 5 cells per 6 well (2 ml per well).
Day 4
Setting up the co-culture by combining the differentiated macrophages and melanoma cells in the same plate as described in Figure 1 Day 4.
1. 48 h after the addition of LPS or IL4/IL23, the differentiated THP-1cells are washed 3 times in fresh RPMI/FCS media. One wash consists of careful aspiration of the media and then adding 4 ml of fresh RPMI/FCS media. 
Notes
The most crucial factor in producing reliable and consistent results using this transwell technique is choosing the correct number of the respective melanoma cell line for plating so that they do not over-grow by the end-point of the experiment. There is also an increased risk of contamination due to the handling of the inserts above the wells, which can be reduced by working as swift and clean as possible.
Recipes

DMEM/FCS media
Dulbecco's modified eagle medium supplemented with 1% of Penicillin-streptomycin solution and 10% FCS
RPMI/FCS media
